Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases.

SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

Patients with asthma and T2 diabetes using SGLT2 inhibitors have a significantly decreased mortality risk within 30 days of an asthma exacerbation.

Type 2 diabetes patients starting on SGLT2 inhibitors had a sightly lower risk of autoimmune rheumatic diseases compared with those initiating sulfonylureas, a large retrospective Korean study found.

SGLT2 inhibitors were associated with greater reduction in MACE risk among older adults than younger adults with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer a greater ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...

SAN DIEGO — Patients with cirrhosis treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant reductions in a range of portal hypertension complications and all-cause mortality ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of sodium-glucose cotransporter 2 inhibitors was ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 receptor agonists conferred greater HbA1c reductions in older adults than younger adults. Older adults had ...